CVRx, Inc.

CVRx, Inc. develops Barostim™, the world’s first neuromodulation device for heart failure management. This implantable therapy improves heart function and quality of life by regulating the body's stress response through electrical stimulation of baroreceptors. Clinical studies show significant symptom improvement and safety for patients.